Table 3.
Case control studies comparing CRS and HIPEC with CRS alone as 2nd line therapy
| Ref No | Year of Publication | N | CRS+ HIPEC | CRS | Survival for CRS+ HIPEC | Survival for CRS alone | p Value |
|---|---|---|---|---|---|---|---|
| [67] | 2009 | 26 | 14 | 12 | 58 % (5 yrs. OS) | 17 (5 yrs. OS) | 0.011 |
| [68] | 2011 | 48 | 24 | 24 | 50 % (3 yrs. OS) | 18 % (3 yrs. OS) | <0.01 |
| [69] | 2012 | 67 | 30 | 37 | 68 % (5 yrs. OS) | 42 % (5 yrs. OS) | 0.017 |
| [70] | 2014 | 111 | 27 | 81 | 79 M (Median OS) | 45 M (Median OS) | 0.016 |
| [71] | 2015 | 54 | 32 | 22 | 23 (3 yrs. DFS) | 45 (3 yrs. DFS) | 0.078 |
Abbreviations: SI Single Institution, DFS Disease Free Survival, OS Overall Survival, M Months; yrs. years